HR 2087
116th Congress
House
Health
Administrative law and regulatory procedures
Civil actions and liability
Congressional oversight
Consumer affairs
Health care costs and insurance
Health information and medical records
Insurance industry and regulation
Medicare
Prescription drugs
Retail and wholesale trades
Drug Price Transparency Act
Everywhere this bill has been
5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 21, 2019
Subcommittee Hearings Held.
Apr 5, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2019
Introduced in House
Plain-English summary
Drug Price Transparency Act
This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
What's happening now
Subcommittee Hearings Held.
Committees of jurisdiction
4
Cosponsors
1